Business
Here’s why the Imugene (ASX:IMU) share price is rising 9% today
The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.
PD1-Vaxx is a B-cell immunotherapy designed to treat tumours by producing polyclonal antibodies that block PD-1 signalling, causing an anti-cancer effect.
During mid-afternoon trade, the Imugene shares are up 9.5% to 12 cents.
First checkpoint passed
The Imugene share price is rising deeper into positive territory following the release.
According to Imugene, the CRC cleared the pathway for phase I clinical trials to be proceed with a higher dose of PD1-Vaxx.
Following patient data review, CRC unanimously decided that the immunotherapy…
-
Noosa News11 hours agoFarmer Fred Perry’s 30-year conservation project creates bird haven after years of ‘bashing and burning’
-
Noosa News4 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General10 hours agoBoy dies after being trapped between rocks off NSW beach
-
Noosa News11 hours agoDetectives continue to search for answers on Crystal Beale’s death